<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190121042444N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-11</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>"Investigation of the effect of anesthetic propofol on gene expression"; "Investigation of the effect of the anesthetic Isoflurane on gene expression"</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of two drugs, propofol and isoflurane, as anesthetic agents on gene expression mt-DNA in posterior vertebral fixation surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>34</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74277</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The participants in the study are divided into two groups, control and intervention, using a randomizer software, so that at first, each patient is given a number by the researcher, and it is entered into the IZE Android software, and the output of the patient software is as It introduces groups A and B.
  34 patients will be included in the study and will be divided into two groups of 17 people, Blinding description: Patients are introduced to the data collector to continue the study so that only the numbers A and B are written on the form in the patient's hand, and as a result, the patient and the data collector are not aware of the patient group.</study_design>
      <phase>3</phase>
      <hc_freetext>Lumbar spine injury.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In order to induce anesthesia in all patients, midazolam 0.01 mg/kg, fentanyl 2 kg/mµ, lidocaine 1.5 mg/kg, propofol 2.5-2 mg/kg, and cis-etracurium 0.2 mg/kg will be administered. Then propofol with a dose of 0.1 to 0.2 mg/kg/min is used to maintain anesthesia in group one and isoflurane 1 to 2.5% is used by inhalation in group two. In addition, in both groups, atracurium and fentanyl were repeated every 45 minutes. Blood samples were taken in order to measure the mentioned variables once before induction (Baseline) and once one hour after anesthesia and 24 hours after the end of surgery. EDTA containing is collected. Intervention 2: Control group: No intervention will be performed in this group. Standard treatment will be administrated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the data, such as information about the main consequence or the like, can be shared.

When:
Start of access period from 1402

To whom:
Only for researchers in academic and scientific institutions

Conditions:
Only data analysis is possible

Where to obtain:
Dr. Faranak Behnaz, Address: Tehran, Tajrish Square, Shohada Experience Hospital, Tel: 0098212271174

How to obtain:
After submitting the application, a maximum of one week will be answered

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Faranak Behnaz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shohada Hospital, Tajrish SQ, Tehran , Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985711151</zip>
        <telephone>009821227741174</telephone>
        <email>faranak.behnaz@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehrak Erfanian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shohada Hospital,Tajrish SQ</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985711151</zip>
        <telephone>009821227741174</telephone>
        <email>mehrak_erfanian@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are candidates for elective surgery for posterior stabilization of the lumbar spine
ASA class I-II</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Previous history of surgery
ASA class III or higher
Malignancies
Cardiovascular diseases
Chronic inflammatory diseases
Corticosteroid use
Emergency surgery
Any instability of the patient during surgery
Drug addiction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S30-S39</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Injuries to the abdomen, lower back, lumbar spine and pelvis(S30-S39)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In order to induce anesthesia in all patients, midazolam 0.01 mg/kg, fentanyl 2 kg/mµ, lidocaine 1.5 mg/kg, propofol 2.5-2 mg/kg, and cis-etracurium 0.2 mg/kg will be administered. Then propofol with a dose of 0.1 to 0.2 mg/kg/min is used to maintain anesthesia in group one and isoflurane 1 to 2.5% is used by inhalation in group two. In addition, in both groups, atracurium and fentanyl were repeated every 45 minutes. Blood samples were taken in order to measure the mentioned variables once before induction (Baseline) and once one hour after anesthesia and 24 hours after the end of surgery. EDTA containing is collected.</i_keyword>
      <i_keyword>Control group: No intervention will be performed in this group. Standard treatment will be administrated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Level of mt-DNA. Timepoint: before the intervention and 1 hour after the operation and 1 day after the operation. Method of measurement: Measurement of serum levels in a blood test.</prim_outcome>
      <prim_outcome>Duration of surgery. Timepoint: Surgery start time - surgery end time. Method of measurement: minutes.</prim_outcome>
      <prim_outcome>Bleeding volume. Timepoint: End of surgery. Method of measurement: milliliter.</prim_outcome>
      <prim_outcome>Complications of surgery. Timepoint: First of surgery- End of surgery. Method of measurement: Filling out the questionnaire.</prim_outcome>
      <prim_outcome>Demographic information. Timepoint: The beginning of surgery. Method of measurement: Filling out the questionnaire based on the birth certificate information.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-26</approval_date>
        <contact_name>Ethics committee of Shahid Behesti University of Medical Sciences</contact_name>
        <contact_address>Yaman Ave,Velenjak Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
